1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Pseudobulbar Affect (PBA): new trials by email Literature Review of Pseudobulbar Affect (PBA) trials Research Report on Pseudobulbar Affect (PBA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo - Pseudobulbar Affect (PBA) | Phase 3 | Completed | Avanir Pharmaceuticals | 326 | 2007-12-01 | 2017-04-12 |
Amyotrophic Lateral Sclerosis (1) · Multiple Sclerosis (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Central Nervous System Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Metabolic Diseases (1) · Motor Neuron Disease (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Proteostasis Deficiencies (1) · Spinal Cord Diseases (1) · TDP-43 Proteinopathies (1)
Dextromethorphan (1) · Quinidine (1) · dextromethorphan - quinidine combination (1)
Argentina (1) · Brazil (1) · United States (1)